2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.
Michael J. Morris, MD, clinical director of Genitourinary Medical Oncology Service and Prostate Cancer Section head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses next steps for prostate-specific membrane antigen (PSMA)–targeted PET imaging in prostate cancer.
The next step for PSMA-targeted imaging with 18F-DCFPyL-PET/CT, says Morris, is submitting data from the phase 3 CONDOR and phase 2/3 OSPREY trials to the agency for review. Certainly, physicians who treat patients with prostate cancer in the United States hope that the review yields an FDA approval. In the system, regulatory approval is separate from reimbursement, so the Centers for Medicare and Medicaid Services (CMS) will need to review reimbursement around PSMA imaging.
There are currently 2 different PSMA imaging studies that are on track for review––Gallium-68 PSMA-11 and 18F-DCFPyL. From a prostate cancer community perspective, it is important that these tools be delivered to patients and physicians in order to help them better understand where the patient’s disease is and make more informed decisions regarding the best treatment for patients, concludes Morris.